pembrolizumab

Drug Overview

Pembrolizumab is a groundbreaking cancer treatment that has changed how we fight many types of tumors. It is a type of Immunotherapy and Targeted Therapy. Unlike traditional chemotherapy, which kills both healthy and sick cells, pembrolizumab helps your body’s own immune system find and destroy cancer cells.

Often called a “checkpoint inhibitor,” this drug acts like a key that unlocks the immune system’s power. It is used for many different cancers, making it one of the most versatile medicines in modern oncology.

• Generic name: Pembrolizumab
• US Brand names: Keytruda®
• Drug Class: Programmed Death Receptor-1 (PD-1) Blocking Antibody; Immunotherapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: FDA Approved for over 30 different types of cancer.
  
  Discover pembrolizumab, a breakthrough immunotherapy for various cancers. Consult our hospital’s experts for personalized and advanced care plans.

What Is It and How Does It Work? (Mechanism of Action)

To understand how pembrolizumab works, you first have to understand how cancer “hides.” Your immune system has special cells called T-cells that act like soldiers. These soldiers have a “brake” on them called the PD-1 receptor. This brake stops the T-cells from attacking your healthy organs by mistake.

Cancer cells are very sneaky. They often produce a protein called PD-L1. When this protein connects with the PD-1 brake on the T-cell, it sends a “stop” signal. This essentially puts the T-cell to sleep, allowing the cancer to grow without being noticed.

Pembrolizumab is a laboratory-made antibody that works at the molecular level to fix this:

1. Blocking the Connection: The drug travels through the blood and attaches directly to the PD-1 receptors on your T-cells.
2. Releasing the Brake: By “covering” the PD-1 receptor, the drug prevents the cancer’s PD-L1 protein from ever touching the T-cell.
3. Waking Up the Soldiers: Without the “stop” signal, your T-cells wake up and recognize the cancer cells as a threat.
4. The Attack: The re-activated T-cells then multiply and begin to hunt down and kill cancer cells throughout the body.

FDA-Approved Clinical Indications

Pembrolizumab is approved for a massive list of cancers. It is often used when a tumor has specific genetic markers called MSI-H or dMMR.

Oncological uses:

• Melanoma: Advanced or stage IIB/IIC skin cancer.
• Lung Cancer: Non-small cell lung cancer (NSCLC), often as a first treatment.
• Head and Neck Cancer: Squamous cell carcinoma.
• Hodgkin Lymphoma: For cases that have returned or didn’t respond to other drugs.
• Kidney Cancer: Renal cell carcinoma (often used with other drugs).
• Breast Cancer: Specifically Triple-Negative Breast Cancer (TNBC).
• Bladder Cancer: Urothelial carcinoma.
• Any Solid Tumor: If the tumor has a specific genetic signature (MSI-H, dMMR, or high TMB).

Non-oncological uses:

• None.

Dosage and Administration Protocols

Pembrolizumab is given as a slow drip into a vein by a healthcare professional.

• 
  Dose Adjustments: One of the benefits of this drug is that no dose adjustments are usually needed for patients with kidney (renal) or liver (hepatic) insufficiency. However, the doctor may pause or stop treatment if the drug causes the immune system to attack healthy organs.

Clinical Efficacy and Research Results

Recent clinical data from 2020 to 2025 shows that pembrolizumab significantly extends life across many cancers.

• Lung Cancer (KEYNOTE-024): Long-term data shows that for certain lung cancer patients, the 5-year survival rate was nearly doubled (31.9%) compared to those who only received chemotherapy (16.3%).
• Melanoma: In patients whose melanoma was removed by surgery, pembrolizumab reduced the risk of the cancer returning or death by roughly 35% to 43% in recent follow-up studies.
• Triple-Negative Breast Cancer: When added to chemotherapy before surgery, the drug helped more patients achieve a “complete response” (no visible cancer left) compared to chemotherapy alone.
• Survival: In many advanced cancers, patients are now living for years instead of months because of this Immunotherapy.

Safety Profile and Side Effects

Because pembrolizumab “wakes up” the immune system, the main side effects happen when the immune system gets too excited and starts attacking healthy parts of the body. These are called Immune-Related Adverse Events (irAEs).

Black Box Warning:

• There is no official Black Box Warning, but there are strict warnings regarding Immune-Mediated Adverse Reactions that can be fatal if not treated.

Common side effects (>10%)

• Feeling very tired (Fatigue)
• Itchy skin or rash
• Diarrhea
• Cough
• Nausea
• Joint pain

Serious adverse events

• Pneumonitis: Inflammation of the lungs (causes trouble breathing).
• Colitis: Inflammation of the intestines (causes severe diarrhea).
• Hepatitis: Inflammation of the liver.
• Endocrine issues: Problems with the thyroid, adrenal, or pituitary glands (may require lifelong hormone pills).
• Nephritis: Inflammation of the kidneys.

Management strategies

• Steroids: If a serious immune reaction happens, the doctor will give steroids (like prednisone) to calm the immune system.
• Pausing Treatment: The drug is often stopped until the side effect is better.

Research Areas

In the fields of Regenerative Medicine and stem cell research, scientists are looking at how pembrolizumab affects the “bone marrow niche.” Current research is exploring whether combining this drug with certain stem cell growth factors can help the body rebuild a healthy immune system after heavy treatment. Researchers are also testing “personalized vaccines” alongside pembrolizumab to see if they can teach the immune system to be even more precise in finding cancer.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Biomarker Testing: Tests for PD-L1 levels, MSI, or dMMR to see if the drug is likely to work for you.
• Liver and Kidney Function: Blood tests to establish a baseline.
• Thyroid Tests: To check how your metabolism is working.

Precautions during treatment

• Report Everything: Even a mild cough or slightly loose stools should be reported to your doctor immediately. Early treatment of side effects prevents them from becoming serious.
• Steroid Awareness: Do not start any new steroids without your oncologist’s permission, as they can “turn off” the drug’s effect.

“Do’s and Don’ts” list

• DO carry a “Patient Wallet Card” that says you are taking an immunotherapy drug.
• DO tell any doctor you see (like a dentist or ER doctor) that you are on pembrolizumab.
• DON’T ignore a fever or new shortness of breath.
• DON’T stop the treatment without talking to your oncologist.

Legal Disclaimer

This guide is for informational purposes only. It is not medical advice. Pembrolizumab is a powerful prescription medication and should only be used under the direct care of a board-certified oncologist. Side effects can be serious or life-threatening. Always consult your healthcare provider before making any changes to your treatment plan.